Published in final edited form as:

J Nat Prod. 2016 January 22; 79(1): 116–125. doi:10.1021/acs.jnatprod.5b00779.

Higginsianins A and B, Two Diterpenoid α -Pyrones Produced by *Colletotrichum higginsianum*, with *in Vitro* Cytostatic Activity

Alessio Cimmino[†], Veronique Mathieu[‡], Marco Masi[†], Riccardo Baroncelli[§], Angela Boari^{||}, Gennaro Pescitelli[#], Marlène Ferderin[†], Romana Lisy[†], Marco Evidente[†], Angela Tuzi[†], Maria Chiara Zonno^{||}, Alexander Kornienko[⊥], Robert Kiss[‡], and Antonio Evidente^{*†}

[†]Dipartimento di Scienze Chimiche, Università di Napoli Federico II, Complesso Universitario Monte Sant'Angelo, Via Cintia 4, 80126, Napoli, Italy

[‡]Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), Brussels, Belgium

[§]Laboratoire Universitaire de Biodiversité et Ecologie Microbienne, University of Western Brittany, Avenue du Technopole, Plouzané, 29280 Brest, France

^{||}Istituto di Scienze delle Produzioni Alimentari, Consiglio Nazionale delle Ricerche, Via Amendola 122/O, 70125 Bari, Italy

[#]Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Via Moruzzi 3, 56124 Pisa, Italy

[⊥]Department of Chemistry and Biochemistry, Texas State University, San Marcos, Texas 78666, United States

Abstract

Two new diterpenoid α -pyrones, named higginsianins A (**1**) and B (**2**), were isolated from the mycelium of the fungus *Colletotrichum higginsianum* grown in liquid culture. They were characterized as 3-[5a,9b-dimethyl-7-methylene-2-(2-methylpropenyl)dodecahydronaphtho[2,1-*b*]-furan-6-ylmethyl]-4-hydroxy-5,6-dimethylpyran-2-one and 4-hydroxy-3-[6-hydroxy-5,8a-dimethyl-2-methylene-5-(4-methylpent-3-enyl)decahydronaphthalen-1-ylmethyl]-5,6-dimethylpyran-2-one, respectively, by using NMR, HRESIMS, and chemical methods. The structure and relative configuration of higginsianin A (**1**) were confirmed by X-ray diffractometric analysis, while its absolute configuration was assigned by electronic circular dichroism (ECD) experiments and calculations using a solid-state ECD/TDDFT method. The relative and absolute configuration of higginsianin B (**2**), which did not afford crystals suitable for X-ray analysis, were determined by NMR analysis and by ECD in comparison with higginsianin A. **1** and **2** were the C-8 epimers of subglutinol A and diterpenoid BR-050, respectively. The evaluation of **1** and **2** for antiproliferative activity against a panel of six cancer cell lines revealed that the IC₅₀ values, obtained with cells reported to be sensitive to proapoptotic stimuli, are by more than 1 order of

*Corresponding Author: Tel: +39 081 2539178. evidente@unina.it.

Supporting Information: The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jnatprod.5b00779.

Notes: The authors declare no competing financial interest.

magnitude lower than their apoptosis-resistant counterparts (1 vs >80 μM). Finally, three hemisynthetic derivatives of **1** were prepared and evaluated for antiproliferative activity. Two of these possessed IC_{50} values and differential sensitivity profiles similar to those of **1**.

Graphical abstract

Fungal secondary metabolites have been an excellent source of new antibiotics, antifungals, herbicides, and antitumor compounds.^{1,2} They belong to different classes of organic compounds such as aromatics, amino acids, coumarins, isocoumarins, cytochalasans, ethanones, furopyrans, nonenolides, oxazatricycloalcalenones, and terpenes, among many others. Therefore, the continued exploration of fungi in search of structurally new products with promising bioactivities is an important area of research.

Colletotrichum is a fungal genus comprising a large number of endophytic, saprophytic, and plant pathogenic species. It is one of the most economically important plant pathogenic genera that causes anthracnose disease of fruits and leaves in a wide range of hosts, resulting in severe crop reduction and conspicuous postharvest losses of tropical and subtropical cereals, grasses, legumes, vegetables, and tree fruits.^{3–11} For this reason species belonging to this genus have been the subject of extensive studies involving their pathogenesis, morphology, multigene analysis, physiology, host range, and disease life cycle. However, because of the large size of the genus, the production of secondary metabolites by various species is only partially explored (for a review, see Carcía-Paión and Collado, 2003).¹² Thus, we evaluated the culture filtrates and mycelia of ca. 100 strains belonging to many species of the genus *Colletotrichum* in order to find novel metabolites with potential phytotoxic, antibiotic, antifungal, and anticancer activities. One of the evaluated species was a strain of *Colletotrichum higginsianum*, a fungus that belongs to *C. destructivum* species complex¹³ and causes anthracnose leaf spot disease on many cultivated forms of *Brassica*. The present study reveals that this fungus produces a mycelium, whose extract displays *in vitro* antitumor activity. Bioactivity-guided fractionation of this extract resulted in the isolation of two novel diterpenoid α -pyrones, named higginsianins A and B. These compounds were chemically characterized and evaluated for antiproliferative activity against a panel of six cancer cell lines.

Results and Discussion

The EtOAc organic extract was obtained from the maceration of the lyophilized *C. higginsianum* mycelium. The extraction was carried out at room temperature in the dark. The extract was subjected to bioactivity-guided fractionation by evaluating the separated fractions for antiproliferative activity against a number of cancer cell lines as detailed in the Experimental Section. This process yielded two main bioactive metabolites as homogeneous solids, which were named higginsianins A and B (**1** and **2**, 13.3 and 4.4 mg/L, respectively). While **1** crystallized as white needles, **2** proved to be not crystallizable.

Compound **1** had a molecular formula of $C_{27}H_{38}O_4$ as deduced from its HRESIMS spectrum and consistent with nine hydrogen deficiencies. The preliminary investigation of its 1H and ^{13}C NMR spectra (Table 1) showed signals for carbonyl, olefinic, and hydroxy groups consistent with the bands observed in the IR spectrum,¹⁴ while its UV spectrum showed a band typical of an extended conjugated ester.¹⁵ A further investigation of its 1H NMR spectrum (Table 1) showed the presence of a broad doublet ($J = 9.0$ Hz, H-13) at δ 5.14 and two broad singlets (H₂-19) at δ 4.47 and 4.22, belonging to a trisubstituted and a 1,1-disubstituted double bond. Further, a triplet of doublets ($J = 9.0$ and 6.8 Hz, H-12) at δ 4.78 and a broad singlet (H-8) at δ 3.64 were observed and assigned to the two oxygenated methine groups. The 1H NMR spectrum also contained two singlets (Me-26 and Me-27) at δ 2.09 and 1.83 and two broad singlets (Me-15 and Me-16) at δ 1.64 and 1.63, attributed to four vinylic methyls, as well as two singlets (Me-17 and Me-18) at δ 0.88 and 0.86 due to two quaternary methyl groups.¹⁶ On the basis of the couplings observed in the HSQC spectrum,¹⁷ the signals observed in the ^{13}C NMR spectrum at δ 127.3, 111.1, 82.9, 73.0, 25.8, 21.6, 20.7, 18.2, 17.3, and 9.9 were assigned to carbons C-13, C-19, C-8, C-12, C-15, C-18, C-17, C-16, C-26, and C-27.¹⁸ The ^{13}C NMR spectrum also contained a singlet typical of a carbonyl of an α -pyrone ring, six singlets of olefinic carbons, one of which was oxygenated, two quaternary carbons, two methines, and six methylene groups for a total of 27 carbons, consistent with a polycyclic diterpene ring system joined to a tetrasubstituted α -pyrone ring. Indeed, in the COSY spectrum¹⁷ the olefinic proton H-13 was coupled with the two methyl groups (Me-15 and Me-16) and with the proton of the adjacent oxygenated methine (H-12). The methine proton (H-12) was, in turn, coupled with the protons of the adjacent methylene group (H₂-11), which resonated as two double doublets ($J = 12.8$ and 6.6 Hz and $J = 12.8$ and 9.0 Hz, respectively) at δ 2.15 and 1.17. The olefinic protons (H₂-19) were coupled with the protons of the methylene group (H₂-2), which resonated as a broad doublet of double doublets ($J = 17.9$, 13.5, and 4.8 Hz) and a multiplet at δ 2.39 and 2.10, respectively. The olefinic protons (H₂-19) were also coupled with the methine proton (H-4), which appeared as a double doublet ($J = 10.9$ and 5.3 Hz) at δ 2.03 through coupling with the adjacent methylene protons (H₂-20). The methylene protons (H₂-20) resonated as two double doublets ($J = 13.7$ and 10.9 Hz and $J = 13.7$ and 5.3 Hz) at δ 2.61 and 2.55. The methylene protons (H₂-2) were coupled with those of the adjacent methylene group (H₂-1), which appeared as a broad doublet ($J = 13.5$) and a double triplet ($J = 13.5$ and 4.3 Hz) at δ 1.45 and 1.30, respectively. The methylene group (H₂-1) was, in turn, coupled with the adjacent methine proton (H-10), which was observed as a multiplet at δ 1.65. The proton (H-8) of the oxygenated methine carbon appearing as a broad singlet at δ 3.64 was coupled

with the protons of the adjacent methylene group (H₂-7), which resonated as two multiplets at δ 1.74 and 0.78. The methylene protons (H₂-7), in turn, were coupled with the protons of the adjacent methylene group (H₂-6), which appeared as two multiplets at δ 1.94 and 0.92. The couplings observed in the HSQC spectrum allowed us to assign the signals at δ 56.1, 48.9, 38.5, 32.0, 29.4, 24.6, 22.7, and 21.4 to their corresponding methine and methylene carbons C-4, C-11, C-10, C-2, C-6, C-1, C-7, and C-20. In addition, the carbonyl, six quaternary olefinic, and two aliphatic carbons observed δ 165.1, 163.7, 155.7, 148.5, 134.6, 127.3, 111.1, 105.8, 102.9, and 44.1 and 37.6 were assigned to C-25, C-22, C-24, C-3, C-14, C-13, C-19, C-23, C-21, and C-9 and C-5 on the basis of the couplings observed in the HMBC spectrum. In particular, the couplings between C-25 and H₂-20, C-22 and H₂-20 and Me-27, C-24 and Me-26, C-3 and H-4 and H-2A, C-14 and Me-15 and Me-16, C-23 and Me-26 and Me-27, C-21 and H₂-20, and C-9 and H₂-7, H-11A and Me-17 and C-5 with H-7A, H-10 and Me-18 were detected. Thus, the chemical shifts of all the protons and corresponding carbons of **1** were assigned as shown in Table 1. Some of the HMBC couplings allowed us to identify the substituents and their locations on the α -pyrone residue, the location of the 2,2-dimethylethenyl side chain, and that of the exocyclic methylene. In particular, the 3-(5,6-dimethyl-4-hydroxy)- α -pyronyl residue appeared linked to the methylene H₂C-20, which, in turn, was linked to C-4 because of the coupling of C-4 with H₂-20. The dimethylethenyl was determined to be attached to C-12 by the coupling observed between its geminal proton (H-12) and C-13. The carbon C-3 of the exocyclic methylene group was included in a six-membered ring due to the coupling observed between C-3 and H-4 and H-2A, C-4 and Me-18, C-5 and H-10, C-2 and H₂-19, and C-1 and H-10. Ring A appeared to be joined with ring B through the carbons C-5 and C-10 because of the couplings observed between C-5 and H-7A and between C-6 and Me-18. The Me-18 was located at C-5 because of the couplings of Me-18 with C-5 and C-6. Finally, the residual unsaturation was due to a 2,3,3,5-tetrasubstituted tetrahydrofuran ring, which as mentioned above bears the dimethylethenyl group at C-12. This ring was determined to be joined to the decahydronaphthalene system through carbons C-9 and C-8 due to the couplings observed between C-6 and H-8, C-8 and Me-17, and C-9 and H₂-7 and Me-17. The latter coupling also allowed us to establish that Me-17 was attached to C-9.

On the basis of the above analysis higginsianin A (**1**) was determined to be 3-[5a,9b-dimethyl-7-methylene-2-(2-methylpropenyl)dodecahydronaphtho[2,1-*b*]furan-6-ylmethyl]-4-hydroxy-5,6-dimethylpyran-2-one. The structure assigned to **1** was supported by all of the couplings observed in the HMBC spectrum (Table 1) and by its HRESIMS spectrum, which gave the sodium cluster [M + Na]⁺ at m/z 449.2665 and, when the same spectrum was recorded in negative mode, the pseudomolecular ion [M – H][–] at m/z 425.2665.

The structure was unambiguously confirmed by the X-ray analysis of suitable crystals obtained as white needles by slow evaporation of a MeOH–EtOAc mixture (1:3). An ORTEP view of the molecular structure is shown in Figure 2. Compound **1** crystallizes in the triclinic *P*1 space group with two independent molecules (named A and B) in the unit cell. Bond lengths and angles in **1** are in the normal range. In particular, bond distances at the tetrasubstituted heterocyclic six-membered ring confirm the α -pyrone identity of the group.

The two independent molecules A and B differ only by the orientation of the α -pyrone due to its rotation by 180° around the C(20)–C(21) bond. The molecule of compound **1** consists of a polycyclic ring system incorporating the *trans*-decahydronaphthalene system fused to the tetrahydrofuran ring. The energetically more stable chair conformation is observed for the six-membered rings A and B, while the five-membered ring C adopts an envelope conformation with C-9 at the flap position. In ring A, the geometry at C-3 and the C(3)–C(19) bond distance clearly indicate the presence of an exocyclic double bond. The molecular geometry of **1** features *trans* A/B and *cis* B/C junctions within the polycyclic ring system, with the α -pyrone-CH₂– group in the axial position at C-4 and the dimethylethenyl group in the equatorial position at C-12. In this way the molecule assumes an overall folded shape.

In the absence of a strong anomalous scatterer, it was possible to determine only the relative and not the absolute configuration by X-ray analysis. Six chirality centers are present in the molecule at C-4/C-5/C-8/C-9/C-10/C-12, whose relative configuration is *R/R/S/R/S*. In the crystal packing, the chains of molecules A and chains of molecules B running along the *a*-axis are formed via intermolecular O–H...O=C hydrogen bonds. The relative configuration determined by X-ray analysis was in agreement with the correlations observed in the NOESY spectrum (Table 2),¹⁷ in particular with the cross-peak between H-8 and Me-17, which confirmed the *cis* stereochemistry of the junction between B and C rings.

The structure assigned to **1** is closely related to those of subglutinols A and B (**6** and **7**, Figure 1), two epimeric diterpenoid pyrones isolated from *Fusarium subglutinans* and manifesting immunosuppressive activity.¹⁹ When the set of data obtained for **1** was compared with the literature data reported for subglutininol A,¹⁹ the physical properties (mp and $[\alpha]_D^{25}$) were different, whereas the spectroscopic data (IR, UV, and ¹H and ¹³C NMR) were similar. This is in agreement with the structure assigned to **1**, which appeared to be an epimer of subglutininol A differing by the *cis* stereochemistry at the B/C ring junction. Indeed, as expected, the ¹H NMR spectra of **1** and subglutininol A differed by the ³J_{H,H} coupling constants measured for protons H-8 and H₂-7. For subglutininol A, one of the two ³J_{H,H}'s amounted to 11.5 Hz,¹⁹ indicating an *anti* arrangement, while for **1** both ³J_{H,H}'s were small, indicating a double *gauche* orientation between H-8 and H₂-7. Furthermore, H-12 had the α -orientation in **1**, similar to that reported for subglutininol A, but opposite to the β -position found in its 12-epimer subglutininol B (**7**). Consequently, the couplings between H-12 and H₂-11 in **1** are similar to those observed in subglutininol A.

The absolute configuration of **1** was investigated by means of electronic circular dichroism (ECD) spectroscopy. Figures 3 and 4 show the absorption and ECD spectra measured for (–)-**1** in methanol solution and in the solid state (dispersed in KCl matrix). The two ECD spectra are consistent with each other and show two major negative bands, namely, a very broad weaker band in the 250–350 nm region and a stronger one centered around 205 nm. The two ECD bands correspond to the two major absorption bands mainly associated with the transitions of the substituted α -pyrone chromophore and, at short wavelengths, of the two alkenes. The solid-state ECD spectrum shows minor additional features in the 215–240 nm region, whereas only a shoulder is visible in the solution spectrum. The consistency between the solution and solid-state spectra demonstrates that the effects of intermolecular

exciton couplings in the crystals are negligible.²⁰ The availability of the solid-state X-ray structure of **1** allowed its utilization as input geometry for calculating the ECD spectrum with time-dependent DFT²¹ for comparison with the solid-state experimental spectrum. This technique, known as the solid-state ECD/TDDFT approach, avoids the uncertainty associated with a conformational analysis and the use of optimized geometries^{22,23} and has allowed reliable configurational assignments of several natural products in recent years.^{24,25} In the current case, the two independent molecules found in the unit cell were considered together in the TDDFT calculation (inset in Figure 4), which was run at the CAM-B3LYP/TZVP level on (4*R*,5*R*,8*R*,9*S*,10*R*,12*S*)-**1**. The calculated spectrum (Figure 4) compares well with the experimental solid-state CD spectrum. In particular, the negative sign, relative intensity, and position of the two major ECD bands are reproduced. The unusually broad first ECD band is probably related to an effect intrinsic to the solid state, possibly including the distortion of the pyrone ring. In fact, the band is less broad in the solution spectra, and a single π - π^* transition centered on the α -pyrone is calculated in this region. The agreement between the spectra shown in Figure 4 allowed us to assign the absolute configuration of higginsianin A as (-)-(4*R*,5*R*,8*R*,9*S*,10*R*,12*S*)-**1**. This assignment matches that of subglutinol A (**6**), whose absolute configuration was determined by total synthesis.²⁶ The two natural products differ, however, in the configuration at C-8, leading to their epimeric relationship.

To obtain the initial structure–activity relationship, **1** was converted to three semisynthetic derivatives (**3**–**5**). Thus, acetylation of **1** with acetic anhydride in pyridine gave the corresponding 22-*O*-acetyl derivative (**3**, Figure 1). Its IR spectrum did not contain the hydroxy band, and the ¹H NMR spectrum differed from that of **1** by the presence of the singlet at δ 2.31 due to the acetyl group. The ESIMS spectrum gave the ions corresponding to [2M + K]⁺, [2M + Na]⁺, [M + Na]⁺, and [M + H]⁺ at *m/z* 974, 958, 491, and 469. Furthermore, by treatment with an ethereal solution of diazomethane, **1** gave a mixture of two derivatives, **4** and **5** (Figure 1). Derivative **4** was the expected C-22 methyl ether²⁷ whose IR spectrum did not show any hydroxy band. Its ¹H NMR spectrum differed from that of **1** by the presence of the singlet of the OMe group at δ 3.86. Its EIMS spectrum contained the ions corresponding to [2M + K]⁺, [2M + Na]⁺, [2M + H]⁺, [M + K]⁺, [M + Na]⁺, and [M + H]⁺ at *m/z* 919, 903, 881, 479, 463, and 441. The structure of derivative **5** was determined by IR, NMR, and MS techniques and is shown in Figure 1. Its IR spectrum still contained the hydroxy band, and its ¹H NMR spectrum differed from that of **1** by the presence of a broad singlet at δ 3.72 due to the H₂-28 protons. The ESIMS contained the ions corresponding to [2M + K]⁺, [2M + Na]⁺, [M + K]⁺, [M + Na]⁺, and [M + H]⁺ at *m/z* 919 and 903, 479 and 463, and 441. The interesting formation of **5** can be explained with the proposed mechanism shown in Figure 5. Specifically, the mechanism involves the oxonium ylide intermediate **I**, which undergoes a rearrangement through the expansion of ring C, yielding **5**. The alternative derivative showing the insertion of a methylene group between C-12 and O atoms of the furane ring was ruled out by the spectroscopic data of **5**. In fact, the ¹H NMR spectrum of **5** showed for H-12 and H₂-28 signals typical for oxygenated methine (td, *J* = 8.3 and 7.2 Hz) and methylene (br s) at δ 4.81 and 3.72, respectively, very similar as in **1**. Instead, with respect to **1**, H-8 appeared upfield shifted (δ 2.07) at δ 1.57.

Higginsianin B (**2**) had a molecular formula of $C_{27}H_{40}O_4$ as deduced from its HRESIMS, consistent with eight hydrogen deficiencies, one less than was observed with **1**. When its 1H and ^{13}C NMR spectra (Table 1) were compared to those of **1**, they differed only by the signal of C-12 bearing the dimethylethenyl side chain. The 1H NMR spectrum of **2** contained the signal of a new methylene group (H_2 -12), whose protons appeared both as multiplets at δ 2.11 and 1.85, both upfield shifted with respect to those of **1** (δ 2.67 and 2.93). As expected, in the ^{13}C NMR spectrum the signal for C-12, found at δ 21.3, appeared as a triplet instead of a doublet and was also upfield shifted (δ 51.7). These results indicated that the 2,3,3,5-tetrasubstituted tetrahydrofuran ring found in **1** was open in **2**, resulting in the methylene group (H_2 -12) and the secondary hydroxy at C-8. The chemical shifts of all protons and the corresponding carbons of **2**, which were assigned on the basis of the couplings observed in the COSY, HSQC, and HMBC spectra, are shown in Table 1. Thus, higginsianin B (**2**) was determined to be 4-hydroxy-3-[6-hydroxy-5,8a-dimethyl-2-methylene-5-(4-methylpent-3-enyl)decahydronaphthalen-1-yl-methyl]-5,6-dimethylpyran-2-one. This structural assignment was confirmed by the HRESIMS spectrum, which contained the $[M + Na]^+$ ion at 451.2820. When the same spectrum was recorded in negative-mode HR, the pseudomolecular ion $[M - H]^-$ was recorded at m/z 427.2826.

The relative configuration of **2** appeared to be the same as that of **1**, as deduced from the correlations observed in the NOESY spectrum (Table 2). The absolute configuration of **2** was established by comparison of its ECD spectrum with that of **1** (Figure 3). Not surprisingly, the two compounds have very similar spectra in the entire measured range with the close similarity of all major bands. Moreover, the structural difference between **1** and **2** was observed in the region far from the main α -pyrone chromophore, whereas the environment in the immediate proximity to this chromophore was exactly the same. Therefore, **2** was assigned the same absolute configuration as **1**, which is $(-)-(4R,5R,8R,9S,10R)$ -**2**. Higginsianin B (**2**) appeared to be the C-8 epimer of the diterpenoid BR-050 (**8**) isolated from the insect pathogenic fungus *Torribiella luteorostrata* together with the new macrocyclic metabolites named torribiellutins A–C.²⁸

The *in vitro* antiproliferative activity of compounds **1–5** was determined by means of the MTT colorimetric assay using five human and one murine cancer cell line (Table 3). The five human cancer cell lines included the Hs683 oligodendroglioma, the U373 glioblastoma (GBM), the A549 non-small-cell lung cancer (NSCLC), the MCF-7 breast carcinoma, and the SKMEL-28 melanoma models. The murine cell line was the B16F10 melanoma model. Our previous studies showed that the Hs683^{29–31} and B16F10 cells^{32,33} are sensitive to pro-apoptotic stimuli, whereas the U373^{29–31} and SKMEL28³³ cell lines are more resistant to pro-apoptotic stimuli. The A549 cell line also displays some levels of resistance to pro-apoptotic stimuli,³⁴ while the MCF-7 cells have inefficient caspase-3, which plays a major role in apoptotic cell death.³⁵ The data in Table 3 clearly show that the apoptosis-resistant cancer cell subpanel, which included U373 GBM, SKMEL-28 melanoma, A549 NSCLC, and MCF-7 breast cancer cells, was significantly less sensitive (double-digit micromolar IC_{50} 's) to the antiproliferative effects induced by compounds **1–4** than Hs683 oligodendroglioma and B16F10 melanoma cells, lacking such apoptosis resistance (single-digit and submicromolar IC_{50} 's). In contrast, all cell lines had similar sensitivities to

compound **5**. Thus, the differential sensitivities in this cancer panel were independent of whether the compounds contained the closed (**1**, **3**, and **4**) or open (**2**) tetrahydrofuran ring C. In contrast, such cell-line-dependent selectivity was lost in compound **5**, containing the tetrahydropyran moiety as ring C. It is likely that the substitution of the pyran for the furan ring fundamentally changes the overall shape of the molecule and thus alters its biological properties. The absence of any difference between **1** and its 22-*O*-acetyl derivative (**3**) could be due to a facile hydrolysis of **3** into **1** by intracellular esterases. However, the similar activity profile of the 22-*O*-methyl derivative (**4**) suggests that perhaps structural alterations in this part of the molecule are not important for activity.

Morphological analyses of the antiproliferative effects associated with **1** in Hs683 oligodendroglioma cells suggest that at the IC₅₀ concentration (~1 μ M; Table 3) this compound induces cytostatic rather than cytotoxic effects (Figure 6). However, at a much higher concentration, i.e., 50 μ M, the antiproliferative effects in Hs683 cancer cells are clearly cytotoxic (Figure 6). In addition, the quantitative video-microscopy (QVM) analysis performed on the Hs683 GBM cell line (Figure 7) indicates that growth of the cells is inhibited by ca. 50% after a 72 h treatment with **1** used at 1 μ M. This is consistent with the MTT measurements (Table 3), revealing an IC₅₀ of 1 μ M after a similar treatment of Hs683 cells for 72 h with **1**. The MTT colorimetric assay determines the levels of metabolically active cells, while the QVM analyses permit the direct visual observation of cells in cell culture. Thus, the two techniques are complementary, and the similar IC₅₀ values determined using these two methods significantly increase the level of confidence in the results shown in Table 3. Finally, the QVM data also indicate that **1** is neither photosensitive nor photoactivable, which is an important attribute of a potential anticancer agent.

In conclusion two new diterpenoid α -pyrones, named higginsianins A (**1**) and B (**2**), were isolated from the mycelium of the fungus *C. higginsianum* grown in liquid culture. Their structures, including relative and absolute configurations of all stereocenters, were fully elucidated using NMR techniques, X-ray crystallography, and electronic circular dichroism experiments. Higginsianin A (**1**) is the C-8 epimer of subglutinol A (**6**), previously isolated from *F. subglutinans*, while higginsianin B (**2**) is the C-8 epimer of diterpenoid BR-050 (**8**), previously isolated from *Torrubiella luteostrata*. These latter compounds did not show antiproliferative activity, but **6** exhibited anti-inflammatory activity with **8**, which also showed antimalarial property. Instead, higginsianins A and B, as well as a number of semisynthetic analogues, were found to possess promising antiproliferative effects in a panel of six cancer cell lines, as determined independently with the MTT colorimetric assay and quantitative videomicroscopy. This supports the importance of the stereochemical differences in determining the biological activity. Furthermore, the promising cytostatic, rather than cytotoxic, activity found with the new diterpenoids warrants their further study as potential anticancer agents.

Experimental Section

General Experimental Procedures

Melting points were measured on a Gallenkamp melting point apparatus; optical rotations were measured in a MeOH solution on a Jasco P-1010 digital polarimeter; ECD spectra were recorded on a JASCO J-815 spectropolarimeter in MeOH. Solid-state ECD spectra were measured with the KCl pellet technique, described in Pescitelli et al., 2009.²⁴ IR spectra were recorded as a glassy film on a PerkinElmer Spectrum One FT-IR spectrometer, and UV spectra were recorded in MeOH solution on a PerkinElmer Lambda 25 UV/vis spectrophotometer. ¹H and ¹³C NMR spectra were recorded at 500 and 400 and at 125 and 100 MHz, respectively, in CDCl₃ on Bruker spectrometers. The same solvent was used as an internal standard. Carbon multiplicities were determined by DEPT spectra.¹⁷ DEPT, COSY-45, HSQC, HMBC, and NOESY experiments¹⁷ were performed using Bruker microprograms. HRESIMS spectra were recorded on Thermo LTQ Velos, and ESI and APCIMS spectra were recorded on Agilent Technologies 6120 Quadrupole LC/MS instruments. Analytical and preparative TLC were performed on silica gel plates (Merck, Kieselgel 60, F₂₅₄, 0.25 and 0.5 mm, respectively) or on reversed-phase (Whatman, KC18 F₂₅₄, 0.20 mm) plates; the compounds were visualized by exposure to UV light and/or iodine vapors and/or by spraying first with 10% H₂SO₄ in MeOH and then with 5% phosphomolybdic acid in EtOH, followed by heating at 110 °C for 10 min. CC: Silica gel (Merck, Kieselgel 60, 0.063–0.200 mm).

Fungal Strain

The *C. higginsianum* isolate used in this study is IMI 349063 (CABI Culture Collection). The strain was originally collected in 1991 in Trinidad from spot symptoms on a living leaf of *Brassica rapa* subsp. *chinensis* (common name: pak-choi). This strain was selected because it is the most commonly used in research laboratories as a reference for plant pathology, evolutionary analyses, and phylogenetics.^{36,37} The genome of *C. higginsianum* IMI 349063 has also been sequenced (GenBank accession no. CACQ00000000.2), and expression resources are available.³⁶

Extraction and Purification of Higginsianis A and B

Small fragments of mycelium obtained by colonies of *C. higginsianum* actively growing on PDA were used for seeding Roux bottles containing 200 mL of a sterile defined liquid medium named M1-D.³⁸ Bottles were kept in still condition at 25 °C in the dark in an incubator for 4 weeks, then filtered by Whatman no. 4 filter paper. The harvested mycelium was lyophilized (28.2 g from 8.37 L of culture filtrate) and macerated with EtOAc (3 × 1 L) for 24 h at room temperature in the dark. The organic extracts were combined, dehydrated with anhydrous Na₂SO₄, and evaporated under reduced pressure, yielding a brown oil (3.7 g), showing *in vitro* antiproliferative activity (<30 µg/mL; data not shown). This oil was purified by CC eluted with *n*-hexane–acetone (7:3), yielding 10 groups of homogeneous fractions. The residue of the fourth fraction was purified by CC eluted with CHCl₃–*i*-PrOH (95:5), yielding eight groups of homogeneous fractions. The residue of the first fraction (245 mg), of this latter column, was crystallized using EtOAc–*n*-hexane, obtaining higginsianin A (1, 78.9 mg, *R*_f 0.80, Figure 1) as white crystals. The residues of the fifth and sixth fraction

(174.2 and 260.0 mg, respectively) of the first column were combined and further purified by CC, eluted with CH₂Cl₂–acetone (9:1), giving 11 groups of homogeneous fractions. The residue of the fifth fraction (40.7 mg) was crystallized using EtOAc–*n*-hexane, obtaining further amounts of higginsianin A (**1**, 32.7 mg, for a total amount of 111.6 mg, 13.3 mg/L, *R_f* 0.80). **1** was recrystallized using MeOH–EtOAc (1:3) to obtain crystals suitable for X-ray analysis. The eighth fraction of the first column was obtained as a homogeneous solid and identified as higginsianin B (**2**, 37.4 mg, 4.4 mg/L, *R_f* 0.50) as reported below.

Higginsianin A (1), 3-[5a,9b-dimethyl-7-methylene-2-(2-methyl-propenyl)dodecahydronaphtho[2,1-b]furan-6-ylmethyl]-4-hydroxy-5,6-dimethylpyran-2-one—white crystals; mp 160 °C; [α]_D²⁵ –67.3 (*c* 0.3); IR $\nu_{\max}$ 3225, 1666, 1642, 1563 cm^{–1}; UV $\lambda_{\max}$ nm (log ϵ) 293 (3.9); ¹H and ¹³C NMR see Table 1; HRESIMS (+) *m/z* 449.2665 [calcd for C₂₇H₃₈NaO₄ 449.2668, M + Na]⁺; HRESIMS (–) *m/z* 425.2665 [calcd for C₂₇H₃₇O₄ 425.2671, M – H][–].

Higginsianin B (2), 4-hydroxy-3-[6-hydroxy-5,8a-dimethyl-2-methylene-5-(4-methylpent-3-enyl)decahydronaphthalen-1-ylmethyl]-5,6-dimethylpyran-2-one—amorphous solid; [α]_D²⁵ –68.8 (*c* 0.25); IR $\nu_{\max}$ 3255, 1667, 1644, 1571 cm^{–1}; UV $\lambda_{\max}$ nm (log ϵ) 293 (3.8); ¹H and ¹³C NMR see Table 1; HRESIMS (+) *m/z* 451.2820 [calcd for C₂₇H₄₀NaO₄ 451.2824, M + Na]⁺; HRESIMS (–) *m/z* 427.2826 [calcd for C₂₇H₃₉O₄ 427.2833, M – H][–].

22-O-Acetyl Derivative of 1 (3)

Higginsianin A (**1**, 4.0 mg) dissolved in pyridine (10 μ L) was acetylated with acetic anhydride (10 μ L) at room temperature for 1 h. The reaction was stopped by addition of MeOH, and the azeotrope, obtained by the addition of benzene, was evaporated by an N₂ stream. The oily residue (4.3 mg) was purified by preparative TLC eluted with CHCl₃–*i*-PrOH (95:5), to give 22-*O*-acetylhigginsianin A as a homogeneous compound (**3**, *R_f* 0.80, 3.8 mg). Derivative 3: IR $\nu_{\max}$ 1723, 1642, 1627, 1580, 1181 cm^{–1}; UV $\lambda_{\max}$ nm (log ϵ) 302 (3.5); ¹H NMR, δ 5.22 (1H, br d, *J* = 9.1, H-13), 4.77 (1H, td, *J* = 9.1 and 7.2 Hz, H-12), 4.59 (1H, br s, H-19), 4.32 (1H, br s, H-19'), 3.71 (1H, br s, H-8), 2.65 (1H, m, H-20), 2.55 (2H, m, H-20' and H-2), 2.31 (3H, s, MeCO), 2.21 (3H, br s, Me-26), 2.17 (1H, m, H-4), 2.10 (1H, m, H-2'), 1.87 (1H, m, H-11'), 1.79 (3H, br s, Me-27), 1.71 (3H, s, Me-15), 1.70 (3H, s, Me-16), 1.65 (1H, m, H-6), 1.57 (2H, m, H-10 and H-7), 1.40 (1H, m, H-1), 1.28 (1H, m, H-1'), 1.25 (1H, m, H-11'), 0.98 (3H, s, Me-17), 0.96 (3H, s, Me-18), 0.88 (2H, m, H-6' and H-7'); ESIMS (+) *m/z* 974 [2M + K]⁺, 958 [2M + Na]⁺, 491 [M + Na]⁺, 469 [M + H]⁺.

Reaction of Higginsianin A with Diazomethane

To higginsianin A (**1**, 6.0 mg) dissolved in MeOH (2 mL) was added an ethereal solution of diazomethane (200 μ L). The reaction was carried out overnight at room temperature in the dark. The reaction was stopped by evaporation under a N₂ stream. The residue (6.2 mg) was purified by TLC, eluted with *n*-hexane–acetone (8:2), yielding derivatives **4** and **5**, both as homogeneous compounds (2.9 and 2.1 mg, *R_f* 0.28 and 0.39). Derivative 4: IR $\nu_{\max}$ 1671, 1644, 1601 cm^{–1}; UV $\lambda_{\max}$ nm (log ϵ) 302 (3.5); ¹H NMR δ 5.23 (1H, br d, *J* = 8.3, H-13),

4.77 (1H, td, $J = 8.3$ and 7.2 Hz, H-12), 4.51 (1H, br s, H-19), 4.19 (1H, br s, H-19'), 3.86 (3H, s, MeO), 3.71 (1H, br s, H-8), 2.62 (1H, dd, $J = 13.5$ and 3.5 Hz, H-20), 2.54 (1H, dd, $J = 13.5$ and 11.4 Hz, H-20'), 2.47 (1H, m, H-2), 2.23 (3H, br s, Me-26), 2.20 (1H, m, H-11), 2.15 (1H, m, H-2'), 1.95 (1H, dd, $J = 11.4$ and 3.5 Hz, H-4), 1.89 (3H, br s, Me-27), 1.79 (1H, m, H-6), 1.71 (6H, s, Me-15 and Me-16), 1.50 (2H, m, H-10 and H-7), 1.41 (1H, m, H-1), 1.28 (1H, m, H-1'), 1.25 (1H, m, H-11'), 0.95 (3H, s, Me-17), 0.93 (3H, s, Me-18), 0.82 (2H, m, H-6' and H-7'); ESIMS (+) m/z 919 $[2M + K]^+$, 903 $[2M + Na]^+$, 881 $[2M + H]^+$, 479 $[M + K]^+$, 463 $[M + Na]^+$, 441 $[M + H]^+$. Derivative **5**: IR $\nu_{\max}$ 3225, 1670, 1647, 1566 cm^{-1} ; UV $\lambda_{\max}$ nm (log ϵ) 301 (3.3); ^1H NMR, δ 5.23 (1H, br d, $J = 8.3$, H-13), 4.81 (1H, td, $J = 8.3$ and 7.2 Hz, H-12), 4.54 (1H, br s, H-19), 4.28 (1H, br s, H-19'), 3.72 (2H, br s, H₂-28), 2.71 (1H, t, $J = 12.2$ Hz, H-20), 2.67 (1H, dd, $J = 12.2$ and 3.8 Hz, H-20'), 2.46 (1H, br t, $J = 12.6$ Hz, H-2), 2.21 (1H, m, H-11), 2.19 (1H, m, H-2'), 2.18 (3H, br s, Me-26), 2.12 (1H, m, H-6), 2.07 (1H, m, H-4), 1.85 (1H, m, H-1), 1.71 (6H, s, Me-15 and Me-16), 1.70 (2H, m, H-10 and H-7), 1.57 (1H, m, H-8), 1.42 (2H, m, H₂-1), 1.23 (1H, m, H-11'), 0.96 (3H, s, Me-17), 0.95 (3H, s, Me-18), 0.80 (2H, m, H-6' and H-7'); ESIMS (+) m/z 919 $[2M + K]^+$, 903 $[2M + Na]^+$, 479 $[M + K]^+$, 463 $[M + Na]^+$, 441 $[M + H]^+$.

Crystal Structure Determination of Higginsianin A (1)

Colorless single crystals were obtained at ambient temperature by slow evaporation of a MeOH–EtOAc (1:3) solution. X-ray data collection was performed at 173 K on a Bruker-Nonius KappaCCD diffractometer equipped with graphite-monochromated Mo $K\alpha$ radiation ($\lambda = 0.71073$ Å, CCD rotation images, thick slices, ϕ and ω scans to fill the asymmetric unit). Cell parameters were obtained from a least-squares fit of the θ angles of 201 reflections in the range $3.404^\circ \leq \theta \leq 21.613^\circ$. A semiempirical absorption correction (multiscan, SADABS) was applied. The structure was solved by direct methods (SIR97 package)³⁹ and refined by the full matrix least-squares method on F^2 against all independent measured reflections (SHELXL program of SHELX97 package).⁴⁰ All H atoms were placed in calculated positions and allowed to ride on carrier atoms (C–H in the range 0.95–1.00 Å; $U = 1.2U_{\text{iso}}$ or 1.5 for methyl C); 16 324 intensities were collected in the range $3.04^\circ \leq \theta \leq 25.00^\circ$, 8274 independent reflections and 573 parameters. In the absence of strong anomalous scatterers it was not possible to establish the absolute configuration, the Flack parameter⁴¹ being meaningless. Voids of 206.7 Å³, containing disordered MeOH solvent crystallization molecules, were found in the unit cell. It was not possible to model the disordered solvent, and Platon/SQUEEZE procedure was used to obtain solvent-free reflection data. The final refinement converged to $R_1 = 10.26$ for 3310 observed reflections having $[I > 2\sigma(I)]$ and $wR_2 = 0.2219$ for all data. Final minimum and maximum residual electronic density was -0.357 and 0.456 e/Å³. The presence of disordered crystallization solvent in the structure accounts for the rather high values for R and the residual electronic density. Crystal data: formula C₂₇H₃₈O₄; formula weight 426.57 g/mol; triclinic $P1$; $a = 7.2340(1)$ Å, $b = 10.321(1)$ Å, $c = 19.308(2)$ Å, $\alpha = 85.37(1)^\circ$, $\beta = 79.85(2)^\circ$, $\gamma = 69.87(1)^\circ$; $V = 1332.0(3)$ Å³; $Z = 2$.

CCDC-1057132 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Computational Section

DFT and TDDFT calculations were run with Gaussian'09,⁴² with default grids and convergence criteria. Starting from the X-ray structure of **1**, the two independent molecules of the unit cell were considered together. Missing hydrogen atoms were added, and all hydrogen atoms were optimized with the DFT method at the B3LYP/6-31G(d) level. TDDFT calculations were run using various functionals (B3LYP, CAM-B3LYP, PBE0, M06) and basis sets (SVP, TZVP). The CAM-B3LYP/TZVP combination was employed for the final calculation, including 48 excited states (roots). CD spectra were generated by applying a Gaussian band shape with a 2250 cm⁻¹ exponential half-width, from dipole-length rotational strengths. The difference from dipole-velocity values was negligible. The calculated spectrum in Figure 4 is red-shifted by 10 nm and scaled by a factor of 4 to compare with the experimental spectrum.

Cancer Cell Lines

Human and murine cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), the European Collection of Cell Culture (ECACC, Salisbury, UK), and the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). The code number and histological type of each of the cell lines used in the current study are detailed in Table 3. All the details relating to the culture media used for each cell line are provided in Lefranc et al. 2013.³¹

Determination of the IC₅₀ Growth Inhibitory Concentrations *in Vitro*

The MTT colorimetric assay was used as detailed previously.³¹ The MTT assay measures the number of metabolically active (thus living) cells that are able to transform the yellow substrate 3-(4,5-dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) into the blue formazan dye via a mitochondrial reduction involving succinate dehydrogenase.³¹ The amount of formazan obtained at the end of the experiment (measured by spectrophotometry) is directly proportional to the number of living cells. The determination of the optical density in the control compared to the treated cells therefore enables quantitative measurements of the effects of compounds on the growth of cell lines *in vitro*. Each experimental condition was assessed in six replicates.

Computer-Assisted Phase-Contrast Microscopy (Quantitative Videomicroscopy) Analysis

The direct visualization of the *in vitro* antiproliferative effects induced by **1** (higginsianin A) at 1 and 40 μ M in human Hs683 and U373 glioma cells was performed as detailed elsewhere.³¹

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors V.M., M.F., R.L., and R.K. thank the Belgian Brain Tumor Support (BBTS), the National Cancer Institute (CA186046-01A1), and the Welch Foundation (AI-0045) for financial support. A.E. is associated with the

Istituto di Chimica Biomolecolare del CNR, Pozzuoli, Italy. R.K. is a director of research with the Fonds National de la Recherche Scientifique (FRS-FNRS, Belgium).

References

1. Evidente A, Kornienko A, Cimmino A, Andolfi A, Lefranc F, Mathieu V, Kiss R. *Nat Prod Rep*. 2014; 31:617–627. [PubMed: 24651312]
2. Kornienko A, Evidente A, Vurro M, Mathieu V, Cimmino A, Evidente M, van Otterlo WAL, Dasari R, Lefranc F, Kiss R. *Med Res Rev*. 2015; 35:937–967. [PubMed: 25850821]
3. Sutton, BC. *Colletotrichum, Biology, Pathology and Control*. Bailey, JA.; Jeger, MJ., editors. CAB International; Walliford: 1992. p. 1-26.
4. Hyde KD, Cai L, McKenzie EHC, Yang YL, Zhang JZ, Prihastuti H. *Fungal Diversity*. 2009; 39:96–113.
5. Hyde KD, Chomnuti P, Crous PW, Groenewald JZ, Damm U, Ko TW, Shivas RG, Summerell BA, Tan YPA. *Personia*. 2010; 25:50–60.
6. Lubbe CM, Demman S, Lamprech SC, Crous PW. *Australas Plant Pathol*. 2006; 35:37–41.
7. Abang MM, Abraham WR, Asiedu R, Hoffmann P, Wolf G, Winter S. *Mycol Res*. 2009; 113:130–140. [PubMed: 18929651]
8. Crouch JA, Beirn LA, Cortese LA, Bonos SB, Clarke BB. *Mycol Res*. 2009; 113:1411–1421. [PubMed: 19800001]
9. Kim HR, Lim TH, Kim J, Kim YH, Kim HT. *Plant Pathol J*. 2009; 25:13–20.
10. Masyahit M, Kamaruzaman S, Yahya A, Ghazali M. *Am J Appl Sci*. 2009; 6:902–912.
11. Phoulivong S, Cai L, Chen H, McKenzie EHC, Abdelsalam K, Chukeatiro E, Hyde KD. *Fungal Divers*. 2010; 44:33–43.
12. García-Paíón CM, Collado IG. *Nat Prod Rep*. 2003; 20:426–431. [PubMed: 12964837]
13. Damm U, O'Connell RJ, Groenewald ZJ, Crous PW. *Stud Mycol*. 2014; 79:49–84. [PubMed: 25492986]
14. Nakanishi, K.; Solomon, PH. *Infrared Absorption Spectroscopy*. 2nd. Holden Day; Oakland: 1977. p. 17-44.
15. Scott, AI. *Interpretation of Ultraviolet Spectra of Natural Products*. Pergamon Press LTD; Oxford: 1964. p. 135-164.
16. Pretsch, E.; Bühlmann, P.; Affolter, C. *Structure Determination of Organic Compounds – Tables of Spectral Data*. 3rd. Springer-Verlag; Berlin: 2000. p. 161-243.
17. Berger, S.; Braun, S. *200 and More Basic NMR Experiments: a Practical Course*. 1st. Wiley-VCH; Weinheim: 2004.
18. Breitmaier, E.; Voelter, W. *Carbon-13 NMR Spectroscopy*. VCH; Weinheim: 1987. p. 183-280.
19. Lee JC, Lobkovsky E, Pliam NB, Strobel G, Clardy J. *J Org Chem*. 1995; 60:7076–7077.
20. Padula D, Di Pietro S, Capozzi MAM, Cardellicchio C, Pescitelli G. *Chirality*. 2014; 26:462–470. [PubMed: 24327405]
21. Autschbach J, Nitsch-Velasquez L, Rudolph M. *Top Curr Chem*. 2010; 298:1–98. [PubMed: 21321799]
22. Pescitelli G, Di Bari L, Berova N. *Chem Soc Rev*. 2011; 40:4603–4625. [PubMed: 21677932]
23. Polavarapu P. *Chirality*. 2012; 24:909–920. [PubMed: 22544541]
24. Pescitelli G, Kurtán T, Flörke U, Krohn K. *Chirality*. 2009; 21:E181–E201. [PubMed: 19902530]
25. Pescitelli, G.; Kurtán, T.; Krohn, K. *Comprehensive Chiroptical Spectroscopy*. Berova, N.; Woody, RW.; Polavarapu, P.; Nakanishi, K., editors. Wiley; New York: 2012. p. 145-176.
26. Kim H, Baker JB, Park Y, Park HB, DeArmond PD, Kim SH, Fitzgerald MC, Lee DS, Hong J. *Chem - Asian J*. 2010; 5:1902–1910. [PubMed: 20564278]
27. Carey, FA.; Sandberg, RJ. *Advanced Organic Chemistry Part B Reactions and Synthesis*. Kluwer Academic/Plenum; New York: 2001. p. 152-152.p. 608-609.
28. Pittayakhajonwut P, Usuwan A, Intaradom C, Khoyaiklang P, Supothina S. *Tetrahedron*. 2009; 65:6069–6073.

29. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R, Salmon I. *Cancer*. 2002; 95:641–655. [PubMed: 12209758]
30. Mathieu V, De Nève N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, Lefranc F. *Neoplasia*. 2008; 10:1383–1392. [PubMed: 19048117]
31. Lefranc F, Nuzzo G, Hamdy NA, Fakhr I, Moreno Y, Banuls L, Van Goietsenoven G, Villani G, Mathieu V, van Soest R, Kiss R, Ciavatta ML. *J Nat Prod*. 2013; 76:1541–1547. [PubMed: 23977995]
32. Mathieu V, Le Mercier M, De Neve N, Sauvage S, Gras T, Roland I, Lefranc F, Kiss R. *J Invest Dermatol*. 2007; 127:2399–23410. [PubMed: 17495956]
33. Van Goietsenoven G, Hutton J, Becker JP, Lallemand B, Robert F, Lefranc F, Pirker C, Vandenbussche G, Van Antwerpen P, Evidente A, Berger W, Prévost M, Pelletier J, Kiss R, Kinzy TG, Kornienko A, Mathieu V. *FASEB J*. 2010; 24:4575–4584. [PubMed: 20643906]
34. Mathieu A, Rummelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, Darro F, Kiss R, Salmon I. *Cancer*. 2004; 101:1908–1918. [PubMed: 15386340]
35. Dumont P, Ingrassia L, Rouzeau S, Ribaucour F, Thomas S, Roland I, Darro F, Lefranc F, Kiss R. *Neoplasia*. 2007; 9:766–776. [PubMed: 17898872]
36. O'Connell R, Herbert C, Sreenivasaprasad S, Khati M, Esquerré-Tugayé MT, Dumas B. *Mol Plant-Microbe Interact*. 2004; 17:272–282. [PubMed: 15000394]
37. Baroncelli, R. PhD Thesis. University of Warwick; Coventry, United Kingdom: 2012. *Colletotrichum acutatum sensu lato: from diversity study to genome analysis*.
38. Pinkerton F, Strobel G. *Proc Natl Acad Sci U S A*. 1976; 73:4007–4011. [PubMed: 16592362]
39. Altomare A, Burla MC, Camalli M, Cascarano GL, Giacobozzo C, Guagliardi A, Moliterni AGG, Polidori G, Spagna R. *J Appl Crystallogr*. 1999; 32:115–119.
40. Sheldrick GM. *Acta Crystallogr, Sect A: Found Crystallogr*. 2008; A64:112–122.
41. Flack HD. *Acta Crystallogr, Sect A: Found Crystallogr*. 1983; A39:876–881.
42. Frisch, MJ., et al. *Gaussian'09, Revision D.01*. Gaussian, Inc.; Wallingford, CT: 2013.

Figure 1. Structures of higginsianins A and B (**1** and **2**), higginsianin A derivatives (**3–5**), subglutinols A and B (**6** and **7**), and diterpenoid BR-050 (**8**).

Figure 2.
ORTEP view of higginsianin A (**1**). The two crystallographically independent molecules, molecule A (up) and molecule B (down), are drawn in the same perspective view. Displacement ellipsoids are drawn at the 30% probability level. Only the methine hydrogen atoms are reported for clarity.

Figure 3. Absorption (top) and ECD spectra (bottom) of higginsianins A (**1**, blue) and B (**2**, red) in methanol solution. Sample concentration: **1**, 2.9 mM and 11.7 mM (expansion, dashed blue line); **2**, 2.6 mM.

Figure 4.

Solid blue line: Solid-state ECD spectrum of higginsianin A, (–)-1, as KCl pellet. Dotted black line: TDDFT-calculated ECD spectrum of (4*R*,5*R*,8*R*,9*S*,10*R*,12*S*)-1 at the CAM-B3LYP/TZVP level using the X-ray geometry as the input structure, including two molecules (as in the unit cell, see inset).

Figure 5.
Proposed mechanism for the rearrangement **1** $\rightarrow$ **5**.

Figure 6. Morphological illustrations (phase-contrast microscopy) of the antiproliferative effects induced by higginsianin A (**1**) in Hs683 glioma cells at 1 versus 50 μ M.

Figure 7.

Quantitative effects of higginsianin A (**1**) on the Hs683 glioma cell line. Digitized images were obtained by means of computer-assisted phase-contrast microscopy (quantitative video-microscopy). A global growth ratio (the GGR index) was calculated, resulting in a value that can be directly compared to the IC₅₀ value determined by MTT assay (the hatched horizontal line in the bottom chart, i.e., 1 μM (see Table 3)). First, the global growth (GG) is calculated for each control and for each treated condition at 24, 48, and 72 h by dividing the number of cells on the last image (at 24, 48, and 72 h) by the number of cells on the first image (upper panel; full line: control condition; hatched line: 1 μM; dotted line: 40 μM). The GGR index is obtained by dividing the GG values calculated for cancer cells treated with **1** by the GG values calculated for the control. The experiment was performed once in duplicate, and the data represent the mean ± SEM values. White, gray, and black bars represent the data obtained at 24, 48 and 72 h, respectively.

Table 1

¹H and ¹³C NMR Data of Higginsianins A and B (1 and 2)^a

position	1			2		
	δ_c^b	δ_H (J in Hz)	HMBC	δ_c^b	δ_H (J in Hz)	HMBC
1	24.6	1.45 br d (13.5)	H-10	25.5	1.84 m	H-10
		1.30 dt (13.5, 4.3)			1.53 m	
2	32.0	2.39 br ddd (17.9, 13.5, 4.8)	H ₂ -19	31.7	2.10 m	H-4, H-1A
		2.10 m				
3	148.5		H-4, H-2A	148.5		H ₂ -20, H-4
4	56.1	2.03 dd (10.9, 5.3)	H ₂ -20, Me-18	55.0	2.12 m	H ₂ -20, Me-18
5	37.6		H-7A, H-10, Me-18	37.7		Me-18, H ₂ -20, H-4, H-6
6	29.4	1.94 m	H-8, Me-18	28.1	2.09 m	H-8, Me-18
		0.92 m			0.90 m	
7	22.7	1.74 m		22.5	1.50 m	H ₂ -6
		0.78 m			1.21 dd (12.7, 4.8)	
8	82.9	3.64 br s	H-11A, Me-17	72.2	3.57 br s	H ₂ -11, Me-17
9	44.1		H ₂ -7, H-11A, Me-17	39.0		Me-17
10	38.5	1.65 m	H ₂ -11	40.1	1.68 dd (12.7, 2.6)	H ₂ -11
11	48.9	2.15 dd (12.8, 6.6)	H-10, Me-18	39.6	1.27 m	H-10, Me-18
		1.17 dd (12.8, 9.0)				
12	73.0	4.78 td (9.0, 6.6)	H-11B	21.3	2.11 m	H ₂ -11, H-13
					1.85 m	
13	127.3	5.14 br d (9.0)	H-12, H-11B, Me-15, Me-16	125.2	5.04 br t (7.4)	Me-15, Me-16, H ₂ -11
14	134.6		Me-15, Me-16	131.0		Me-15, Me-16
15	25.8	1.64 br s	Me-16	25.8	1.60 br s	Me-16, H-13
16	18.2	1.63 br s	Me-15	17.3	1.54 br s	Me-15
17	20.7	0.88 s		18.8	0.75 s	
18	21.6	0.86 s		22.5	0.88 s	
19	111.1	4.47 br s		109.9	4.45 br s	H-4
		4.22 br s			4.28 br s	

position	1				2			
	δ_C^b	δ_H (J in Hz)	HMBC		δ_C^b	δ_H (J in Hz)	HMBC	
20	21.4	2.61 dd (13.7, 10.9) 2.55 dd (13.7, 5.3)	H-4		21.8	2.55 d (8.3)	H-4, H ₂ -2	
21	102.9		H ₂ -20		102.5		H ₂ -20	
22	163.7		H ₂ -20, Me-27		165.4		Me-26, Me-27	
23	105.8		Me-26, Me-27		107.4		Me-26, Me-27	
24	155.7		Me-26		154.9		Me-26	
25	165.1		H ₂ -20		166.2		H ₂ -20	
26	17.3	2.09 s	Me-27		16.9	2.09 s	Me-26	
27	9.9	1.83 s	Me-26		9.9	1.81 s	Me-27	

^aThe chemical shifts are in δ values (ppm) from TMS. 2D 1H - 1H (COSY) and ^{13}C - 1H (HSQC) NMR experiments delineated the correlations of all protons and their corresponding carbons.

^bMultiplicities were assigned by the DEPT spectrum.

Table 2
NOESY Data of Higginsianins A and B (1 and 2)

1		2	
irradiated	observed	irradiated	observed
H-8	Me-17, H-7A	H-8	Me-17
H-12	Me-15, Me-16	H-19A	H-19B, H-2B, H-1B
H-19A	H-19B, H-2B	H-19B	H-19A, H-2A, H-4
H-19B	H-19A, H-4		

Table 3
Determination of the Antiproliferative Activity of Compounds 1–5 Using the MTT Colorimetric Assay^a

compound	glioma		carcinoma		melanoma		mean $\pm$ SEM ^e	mean of means $\pm$ SD ^e
	Hs683 ^f	U373	A549	MCF7	SKMEL28	B16F10		
1 (exp 1) ^b	1	63	38	19	73	1	33 $\pm$ 13	39 $\pm$ 8
1 (exp 2)	1	ND ^c	33	82	>100	3	>44 $\pm$ 20	
2 (exp 1)	2	84	42	2	88	25	41 $\pm$ 16	38 $\pm$ 4
2 (exp 2)	2	ND	29	53	89	3	35 $\pm$ 16	
3	1	ND	47	41	84	2	35 $\pm$ 16	_{-d}
4	0.4	ND	16	38	48	1	21 $\pm$ 10	–
5	49	ND	35	24	51	25	37 $\pm$ 6	–
mean $\pm$ SEM	7 $\pm$ 5	81 $\pm$ 8	34 $\pm$ 4	37 $\pm$ 10	76 $\pm$ 8	9 $\pm$ 4		

^aThe data represent the IC₅₀ concentration (μ M), i.e., the compound concentration that reduces by 50% the growth of a given cell line (as compared to the control value) after culturing the cells for 72 h with the compound of interest.

^bEach experiment (“exp”) was carried out in sextuplicate. Two independent experiments (two times sextuplicates) were carried out for compounds **1** and **2**, while one experiment (one time sextuplicate) was carried out for compounds **3**, **4**, and **5**.

^c“ND”, not determined.

^dNot calculated.

^eSEM, means standard error of the mean; SD, standard deviation. SEMs were calculated for $n > 3$, while SDs were calculated for $n < 3$.

^fThe origin and histological type of each cell line analyzed are as follows. Human glioma model lines included the Hs683 oligodendroglioma (ATCC code HTB-138) and the U373 glioblastoma (ECACC code 08061901) cell lines. Melanoma models included the human SKMEL-28 (ATCC code HTB-72) and the mouse B16F10 (ATCC code CRL-6475) cell lines. Human carcinoma models included the A549 NSCLC (DSMZ code ACC107) and the MCF-7 breast (DSMZ code ACC115).